These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

462 related items for PubMed ID: 16291417

  • 1. In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes.
    Isla A, Gascón AR, Maynar J, Arzuaga A, Corral E, Martín A, Solinís MA, Muñoz JL.
    Clin Ther; 2005 Sep; 27(9):1444-51. PubMed ID: 16291417
    [Abstract] [Full Text] [Related]

  • 2. Cefepime and continuous renal replacement therapy (CRRT): in vitro permeability of two CRRT membranes and pharmacokinetics in four critically ill patients.
    Isla A, Gascón AR, Maynar J, Arzuaga A, Toral D, Pedraz JL.
    Clin Ther; 2005 May; 27(5):599-608. PubMed ID: 15978309
    [Abstract] [Full Text] [Related]

  • 3. In vitro AN69 and polysulphone membrane permeability to ceftazidime and in vivo pharmacokinetics during continuous renal replacement therapies.
    Isla A, Gascón AR, Maynar J, Arzuaga A, Sánchez-Izquierdo JA, Pedraz JL.
    Chemotherapy; 2007 May; 53(3):194-201. PubMed ID: 17356270
    [Abstract] [Full Text] [Related]

  • 4. Elimination of piperacillin and tazobactam by renal replacement therapies with AN69 and polysulfone hemofilters: evaluation of the sieving coefficient.
    Arzuaga A, Isla A, Gascón AR, Maynar J, Corral E, Pedraz JL.
    Blood Purif; 2006 May; 24(4):347-54. PubMed ID: 16645266
    [Abstract] [Full Text] [Related]

  • 5. Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis.
    Joy MS, Matzke GR, Frye RF, Palevsky PM.
    Am J Kidney Dis; 1998 Jun; 31(6):1019-27. PubMed ID: 9631848
    [Abstract] [Full Text] [Related]

  • 6. Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients.
    Isla A, Maynar J, Sánchez-Izquierdo JA, Gascón AR, Arzuaga A, Corral E, Pedraz JL.
    J Clin Pharmacol; 2005 Nov; 45(11):1294-304. PubMed ID: 16239363
    [Abstract] [Full Text] [Related]

  • 7. Telavancin and hydroxy propyl-beta-cyclodextrin clearance during continuous renal replacement therapy: an in vitro study.
    Patel JH, Churchwell MD, Seroogy JD, Barriere SL, Grio M, Mueller B.
    Int J Artif Organs; 2009 Oct; 32(10):745-51. PubMed ID: 19943236
    [Abstract] [Full Text] [Related]

  • 8. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment.
    Kruse MW, Lee JJ.
    Am Heart J; 2004 Oct; 148(4):582-9. PubMed ID: 15459586
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of cellulose triacetate dialyzer and polysulfone synthetic hemofilter for continuous venovenous hemofiltration in acute renal failure.
    Pichaiwong W, Leelahavanichkul A, Eiam-ong S.
    J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S65-72. PubMed ID: 17044456
    [Abstract] [Full Text] [Related]

  • 10. Beta 2-microglobulin elimination characteristics during hemofiltration with acrylonitrile and polysulfone membrane hemofilters.
    Kandus A, Ponikvar R, Drinovec J, Pavlin K, Ivanovich P.
    Int J Artif Organs; 1990 Apr; 13(4):200-4. PubMed ID: 2197235
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L, Shen-Tu J, Liu J, Chen J, Wu L, Huang M.
    Clin Ther; 2009 Jul; 31(7):1559-67. PubMed ID: 19695405
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Evaluation of a new polysulfone hemofilter for continuous renal replacement therapy.
    Floris M, Marchionna N, Clementi A, Kim JC, Cruz DN, Nalesso F, Zanella M, Garzotto F, de Cal M, Virzì GM, Brendolan A, Ronco C.
    Blood Purif; 2011 Jul; 32(2):133-8. PubMed ID: 21654165
    [Abstract] [Full Text] [Related]

  • 15. Trace element removal during in vitro and in vivo continuous haemodialysis.
    Churchwell MD, Pasko DA, Btaiche IF, Jain JC, Mueller BA.
    Nephrol Dial Transplant; 2007 Oct; 22(10):2970-7. PubMed ID: 17556411
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Tumor necrosis factor-alpha during continuous high-flux hemodialysis in sepsis with acute renal failure.
    Lonnemann G, Bechstein M, Linnenweber S, Burg M, Koch KM.
    Kidney Int Suppl; 1999 Nov; (72):S84-7. PubMed ID: 10560813
    [Abstract] [Full Text] [Related]

  • 18. A crossover study of the acrylonitrile-co-methallyl sulfonate and polysulfone membranes for elderly hemodialysis patients: the effect on hemodynamic, nutritional, and inflammatory conditions.
    Furuta M, Kuragano T, Kida A, Kitamura R, Nanami M, Otaki Y, Nonoguchi H, Matsumoto A, Nakanishi T.
    ASAIO J; 2011 Nov; 57(4):293-9. PubMed ID: 21499075
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.